Understand Lung Cancer Treatment Options: A Clinical Overview of Current Care

Understand Lung Cancer Treatment Options by examining how clinicians match treatment to the cancer’s type, stage, genetic profile, treatment goals, lung function, and overall health. Lung cancer care commonly combines more than one approach, and every option has potential benefits, risks, and side effects that require discussion with a qualified care team.2

How treatment planning begins

Lung cancer usually begins in the bronchi, bronchioles, or alveoli and may spread to lymph nodes or distant organs. Before treatment is selected, additional tests determine how far the disease has spread through the lungs, lymph nodes, and the rest of the body. This process, called staging, helps distinguish localized disease from cancer requiring treatment throughout the body.13

The two principal categories are non-small cell lung cancer, or NSCLC, and small cell lung cancer, or SCLC. NSCLC represents about 85% of lung cancer cases and may be managed with surgery, radiation, chemotherapy, targeted therapy, immunotherapy, or combinations. SCLC generally spreads more rapidly and is commonly treated with chemotherapy and radiation therapy.38

Surgery and radiation therapy

Surgery is a primary treatment when a lung tumor can be removed completely, particularly in some early-stage NSCLC cases. Procedures may include removal of a small section through wedge resection or segmentectomy, removal of an entire lobe through lobectomy, or removal of a lung through pneumonectomy. Minimally invasive video-assisted thoracic surgery is another approach for some patients.79

Radiation therapy uses high-energy rays to kill cancer cells. It may be used when surgery is unsuitable, before an operation to shrink a tumor, after surgery to address remaining cancer cells, or with other treatments. The balance between tumor control, breathing capacity, nearby-organ exposure, and side effects is especially important for people with emphysema, chronic bronchitis, or other lung problems.37

Drug treatments that act throughout the body

Chemotherapy uses medicines to shrink or kill cancer cells. These drugs may be taken as pills, delivered into a vein, or administered through both routes. Depending on the cancer’s type and stage, chemotherapy can be given before surgery, after surgery, with radiation, or as a central treatment for disease that has spread beyond the original tumor.39

Immunotherapy is designed to help the immune system recognize and attack cancer cells, while targeted therapy blocks particular growth signals, mutations, or proteins in tumor cells. Targeted treatment is not appropriate for every tumor because it depends on finding a relevant biomarker. Molecular or tumor testing can therefore influence which medicines are considered, especially in NSCLC.23

Why biomarkers matter in NSCLC

Biomarker testing examines whether a tumor contains genetic changes or other characteristics that may respond to a specific treatment. Examples identified in the research include EGFR and ALK alterations. Results can help clinicians determine whether a targeted medicine is more suitable than an approach that does not depend on a particular mutation, although the result must be interpreted alongside stage and overall health.38

Genetic testing can also refer to inherited characteristics, which is different from testing the tumor itself. This distinction matters because tumor findings guide cancer treatment, while inherited findings may address family-related risk questions. Treatment decisions remain individualized, since medical conditions, lung function, previous therapy, expected side effects, and the patient’s goals can alter the preferred plan.367

Small cell and advanced lung cancer care

SCLC often requires systemic treatment because of its tendency to spread quickly. The CDC describes chemotherapy and radiation therapy as usual treatments for SCLC, while NSCLC may involve surgery, chemotherapy, radiation, targeted therapy, or combinations. The exact plan depends on whether disease is limited to a treatable area or has spread more broadly.38

When lung cancer is metastatic, treatment may focus on controlling cancer throughout the body, extending life, and relieving symptoms. Surgery or radiation can still have a role in selected circumstances, including treatment of a dominant tumor or a troublesome site. Supportive and palliative care can be included alongside cancer-directed treatment to address symptoms and day-to-day quality of life.278

Risks, trials, and shared decisions

All lung cancer treatments carry potential risks and side effects, although many side effects can be managed. Surgery may affect remaining lung capacity; radiation can expose nearby tissues; chemotherapy can affect healthy fast-dividing cells; and immunotherapy or targeted therapy can produce treatment-specific complications. Existing lung disease and other medical conditions can increase the importance of weighing benefit against functional impact.267

Clinical trials evaluate new treatments or new ways to use established treatments, but participation depends on study requirements and personal medical circumstances. Regulatory review, biomarker results, prior treatment, geographic access, and trial eligibility can all affect which options are available. A shared decision should therefore address treatment goals, alternatives, likely monitoring, side effects, and the practical demands of ongoing care.2910

Sources

1. Cleveland Clinic, “Lung Cancer: Causes, Signs, Diagnosis & Treatment”
2. American Lung Association, “What Are the Types of Lung Cancer Treatment?”
3. Centers for Disease Control and Prevention, “Treatment of Lung Cancer”
4. MSD Manual Consumer Version, “Lung Cancer”
5. Merck Manual Professional Edition, “Lung Carcinoma”
6. European Lung Foundation, “The Benefits and Risks of Lung Cancer Treatments”
7. UT MD Anderson, “Lung Cancer Treatment”
8. Lung Foundation Australia, “What Are My Treatment Options for Lung Cancer?”
9. Fred Hutch Cancer Center, “Common Treatments and Therapies for Lung Cancer”
10. U.S. Food and Drug Administration, “Oncology and Cancer Hematologic Malignancies Approval Notifications”